Long chain omega-3 fatty acids and their oxidized metabolites are associated with reduced prostate tumor growth.
暂无分享,去创建一个
A. Bergeron | K. Robitaille | J. Galano | T. Durand | P. Julien | C. Oger | Y. Fradet | V. Fradet | J. Bilodeau | Jérôme Roy | J. Larose | Nikunj Gevariya
[1] M. V. Van Elswyk,et al. A Scoping Review of Interactions between Omega-3 Long-Chain Polyunsaturated Fatty Acids and Genetic Variation in Relation to Cancer Risk , 2020, Nutrients.
[2] David S. Wishart,et al. Using MetaboAnalyst 4.0 for Comprehensive and Integrative Metabolomics Data Analysis , 2019, Current protocols in bioinformatics.
[3] K. Robitaille,et al. Omega-3 Fatty Acids Survey in Men under Active Surveillance for Prostate Cancer: from Intake to Prostate Tissue Level , 2019, Nutrients.
[4] A. Bergeron,et al. Omega‐3 fatty acids decrease prostate cancer progression associated with an anti‐tumor immune response in eugonadal and castrated mice , 2018, The Prostate.
[5] W. Fraser,et al. F2-isoprostanes and fatty acids profile in early pregnancy complicated by pre-existing diabetes. , 2018, Prostaglandins, leukotrienes, and essential fatty acids.
[6] Sui Huang,et al. Resolvins suppress tumor growth and enhance cancer therapy , 2018, The Journal of experimental medicine.
[7] P. Julien,et al. Modulation of the biomarkers of inflammation and oxidative stress by ruminant trans fatty acids and dairy proteins in vascular endothelial cells (HUVEC). , 2017, Prostaglandins, leukotrienes, and essential fatty acids.
[8] M. Giera,et al. Isoprostanes, neuroprostanes and phytoprostanes: An overview of 25years of research in chemistry and biology. , 2017, Progress in lipid research.
[9] P. Julien,et al. Trans Fatty Acids Suppress TNF-α-Induced Inflammatory Gene Expression in Endothelial (HUVEC) and Hepatocellular Carcinoma (HepG2) Cells , 2017, Lipids.
[10] T. Wakai,et al. Resolvins and omega three polyunsaturated fatty acids: Clinical implications in inflammatory diseases and cancer. , 2016, World journal of clinical cases.
[11] J. Galano,et al. Polymeric nanocapsules prevent oxidation of core-loaded molecules: evidence based on the effects of docosahexaenoic acid and neuroprostane on breast cancer cells proliferation , 2015, Journal of Experimental & Clinical Cancer Research.
[12] Erik Sahai,et al. Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity , 2015, Cell.
[13] C. Serhan,et al. Human Milk Proresolving Mediators Stimulate Resolution of Acute Inflammation , 2015, Mucosal Immunology.
[14] J. Galano,et al. Nonenzymatic lipid mediators, neuroprostanes, exert the antiarrhythmic properties of docosahexaenoic acid. , 2015, Free radical biology & medicine.
[15] W. Fraser,et al. Plasma F2-isoprostane class VI isomers at 12-18 weeks of pregnancy are associated with later occurrence of preeclampsia. , 2015, Free radical biology & medicine.
[16] J. Galano,et al. Total syntheses and in vivo quantitation of novel neurofuran and dihomo-isofuran derived from docosahexaenoic acid and adrenic acid. , 2015, Chemistry.
[17] B. Levy,et al. Lipid mediators in the resolution of inflammation. , 2015, Cold Spring Harbor perspectives in biology.
[18] G. Fan,et al. Roles of resolvins in the resolution of acute inflammation , 2015, Cell biology international.
[19] C. Serhan,et al. Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. , 2014, American journal of physiology. Cell physiology.
[20] J. Galano,et al. Oxygenated metabolites of n-3 polyunsaturated fatty acids as potential oxidative stress biomarkers: total synthesis of 8-F3t-IsoP, 10-F4t-NeuroP and [D4]-10-F4t-NeuroP. , 2014, Chemistry.
[21] P. Julien,et al. Prostatic and Dietary Omega-3 Fatty Acids and Prostate Cancer Progression during Active Surveillance , 2014, Cancer Prevention Research.
[22] I. Thompson,et al. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. , 2014, Journal of the National Cancer Institute.
[23] J. Schwarze,et al. The role of pro-resolution lipid mediators in infectious disease , 2014, Immunology.
[24] A. Bahonar,et al. The Effect of Omega-3 Supplements on Antioxidant Capacity in Patients with Type 2 Diabetes , 2013, International journal of preventive medicine.
[25] D. Rosenberg,et al. Multifaceted roles of PGE2 in inflammation and cancer , 2013, Seminars in Immunopathology.
[26] M. Bryś,et al. Relationship of urinary isoprostanes to prostate cancer occurence , 2012, Molecular and Cellular Biochemistry.
[27] K. Kuroiwa,et al. Antioxidant therapy alleviates oxidative stress by androgen deprivation and prevents conversion from androgen dependent to castration resistant prostate cancer. , 2012, The Journal of urology.
[28] C. Galet,et al. Phase II Prospective Randomized Trial of a Low-Fat Diet with Fish Oil Supplementation in Men Undergoing Radical Prostatectomy , 2011, Cancer Prevention Research.
[29] J. Morrow,et al. Oxidative stress measured by urine F2-isoprostane level is associated with prostate cancer. , 2011, The Journal of urology.
[30] I. Thompson,et al. Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial. , 2011, American journal of epidemiology.
[31] R. DuBois,et al. Eicosanoids and cancer , 2010, Nature Reviews Cancer.
[32] J. Witte,et al. Dietary Omega-3 Fatty Acids, Cyclooxygenase-2 Genetic Variation, and Aggressive Prostate Cancer Risk , 2009, Clinical Cancer Research.
[33] V. Castronovo,et al. Activation of the thromboxane A2 pathway in human prostate cancer correlates with tumor Gleason score and pathologic stage. , 2006, European urology.
[34] J. Lewin,et al. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. , 2004, Cancer research.
[35] G. FitzGerald,et al. F2-isoprostanes as indices of lipid peroxidation in inflammatory diseases. , 2004, Chemistry and physics of lipids.
[36] N. Behrendt,et al. Inuit are protected against prostate cancer. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[37] A. Kafatos,et al. Prostate cancer vs hyperplasia: relationships with prostatic and adipose tissue fatty acid composition. , 2002, Prostaglandins, leukotrienes, and essential fatty acids.
[38] M. Kesavulu,et al. Effect of omega-3 fatty acids on lipid peroxidation and antioxidant enzyme status in type 2 diabetic patients. , 2002, Diabetes & metabolism.
[39] B. Koller,et al. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. , 2001, The Journal of clinical investigation.
[40] J. Morrow,et al. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. , 2000, Free radical biology & medicine.
[41] F. Visioli,et al. Long-chain omega 3 fatty acids: molecular bases of potential antioxidant actions. , 2014, Prostaglandins, leukotrienes, and essential fatty acids.
[42] M. Vohl,et al. Transcriptomic and metabolomic signatures of an n-3 polyunsaturated fatty acids supplementation in a normolipidemic/normocholesterolemic Caucasian population. , 2013, The Journal of nutritional biochemistry.
[43] M. Tjepkema,et al. Cancer patterns in Inuit Nunangat: 1998-2007. , 2012, International journal of circumpolar health.
[44] G. Maskarinec,et al. The effect of migration on cancer incidence among Japanese in Hawaii. , 2004, Ethnicity & disease.